IP Library Granted Patent US 8,501,703
Granted Patent B2
US 8,501,703 · App. 12/065,250 · Granted Aug 6, 2013

Chimeric oligomeric compounds for modulation of splicing

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,501,703
App. No.
12/065,250
Granted
Aug 6, 2013
Kind
B2
Abstract

Disclosed herein are compounds, compositions and methods for modulating splicing of a selected target mRNA. Further provided are uses of the disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Methods of enhancing cellular uptake, modulating tissue distribution and enhancing pharmacological activity of RNase H-independent antisense oligonucleotides are also provided.

Claims (28)

1. A method of modulating splicing of a selected target pre-mRNA in a cell comprising contacting the cell with an oligomeric compound comprising an oligonucleotide consisting of 13 to 30 linked nucleosides which is complementary to the selected target pre-mRNA, and wherein the oligonucleotide has 7-11 separate regions, wherein:

the 5′-most region consists of 1-5 linked modified nucleosides, each comprising a modified sugar moiety;

the 3′-most region consists of 1-5 linked modified nucleosides, each comprising a modified sugar moiety; and

the internal regions alternate between regions of 1-5 linked 2′-deoxyribonucleosides and regions of 1-5 linked modified nucleosides, each comprising a modified sugar moiety,

wherein splicing of the selected target pre-mRNA is modulated.

2. The method of claim 1 , wherein said oligonucleotide comprises 3 separate regions of 2′-deoxyribonucleosides.

3. The method of claim 1 , wherein said oligonucleotide comprises 4 separate regions of 2′-deoxyribonucleosides.

4. The method of claim 1 , wherein each region of 2′-deoxyribonucleosides of said oligonucleotide consists of 2 or 3 nucleosides.

5. The method of claim 1 , wherein the 5′ most region of the oligonucleotide consists of 3 or 4 linked modified nucleosides each comprising a modified sugar moiety.

6. The method of claim 1 , wherein the 3′ most region of the oligonucleotide consists of 4 or 5 linked modified nucleosides each comprising a modified sugar moiety.

7. The method of claim 1 , wherein each sugar modification of each modified nucleoside is selected from the group consisting of 2′-O-methoxyethyl, 2′-fluoro, 2′-dimethylaminooxyethoxy, 2′-dimethylaminoethoxyethoxy, 2′-guanidinium, 2′-O-guanidinium ethyl, 2′-carbamate, 2′-aminooxy, 2′-acetamido and locked nucleic acid.

8. The method of claim 7 , wherein each sugar modification of each modified nucleoside is 2′-O-methoxyethyl.

9. The method of claim 1 , wherein the oligonucleotide consists of 20 to 30 linked nucleosides.

10. The method of claim 1 , wherein the oligonucleotide consists of 15 to 25 linked nucleosides.

11. The method of claim 1 , wherein the oligonucleotide consists of 20 linked nucleosides.

12. The method of claim 11 , wherein the oligonucleotide has 2′-deoxyribonucleosides at positions 3, 4, 5, 7, 8, 9, 11, 12, 13, 15, 16 and 17.

13. The method of claim 11 , wherein the oligonucleotide has 2′-deoxyribonucleosides at positions 4, 5, 6, 9, 10, 11, 14, 15 and 16.

14. The method of claim 11 , wherein the oligonucleotide has 2′-deoxyribonucleosides at positions 4, 5, 8, 9, 10, 13, 14 and 15.

15. The method of claim 11 , wherein the oligonucleotide has 2′-deoxyribonucleosides at positions 5, 6, 7, 9, 10, 11, 13, 14 and 15.

16. The method of claim 11 , wherein the oligonucleotide has 2′-deoxyribonucleosides at positions 5, 6, 7, 9, 10, 13, 14 and 15.

17. The method of claim 11 , wherein the oligonucleotide has 2′-deoxyribonucleosides at positions 5, 6, 7, 10, 11, 12, 15, 16 and 17.

18. The method of claim 11 , wherein the oligonucleotide has 2′-deoxyribonucleosides at positions 6, 7, 8, 10, 11, 12, 14, 15 and 16.

19. The method of claim 11 , wherein the oligonucleotide has 2′-deoxyribonucleosides at positions 6, 7, 8, 11, 12, 13, 16 and 17.

20. The method of claim 1 , wherein the cell is derived from adipose.

21. The method of claim 1 , wherein the cell is derived from liver.

22. The method of claim 1 , wherein the oligonucleotide is complementary to a splice site.

23. The method of claim 22 , wherein the splice site is an aberrant splice site.

24. The method of claim 22 , wherein the splice site is a cryptic splice site.

Assignments (2)
CHANGE OF NAME Recorded Jun 28, 2017
From: ISIS PHARMACEUTICALS, INC.
To: IONIS PHARMACEUTICALS, INC.
Reel/Frame 043029/0338 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2014
From: BENNETT, C. FRANK; DEAN, NICHOLAS M.
To: ISIS PHARMACEUTICALS, INC.
Reel/Frame 032212/0100 →